---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025712"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:47:51.683759+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC

## Summary
- Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.
- Clinically meaningful improvements in objective response rate, PFS, and six-month landmark PFS observed.
- No unexpected safety signals; domvanalimab arms generally well tolerated with safety consistent with individual molecules.
- Detailed results to be presented at ASCO Monthly Plenary Series on December 20, 2022.

## SEC filing metadata
- accession: 0000950170-22-025712
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/0000950170-22-025712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/rcus-20221128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025712
- JSON: https://secwatch.observer/filing/0000950170-22-025712.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.